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mean number of linezolid-nonsusceptible CNS-positive pa-
tients in nearby beds per day.  Conclusions: These results re-
inforce the aspect of rational antibiotic usage, but also high-
light the need for strict infection control measures to pre-
vent the dissemination of linezolid-nonsusceptible CNS. 
 © 2014 S. Karger AG, Basel 
 Introduction 
 Linezolid, a synthetic agent belonging to the oxazolid-
inone family, was introduced in the clinical practice in 
2000 because of its specific activity against multiresistant 
Gram-positive cocci, especially glycopeptide-resistant 
enterococci and methicillin-resistant staphylococci  [1] . It 
is a protein synthesis inhibitor binding to the 50S ribo-
somal subunit, specifically to the peptidyl transferase cen-
ter of bacteria (domain V), thus blocking the precise po-
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 Abstract 
 Background: The aim of the present study was to identify 
risk factors for linezolid-nonsusceptible coagulase-negative 
staphylococci (CNS) dissemination in the intensive care unit. 
 Methods: Among the 246 patients included, 33 revealed a 
linezolid-nonsusceptible CNS-positive culture specimen, 68 
were positive for linezolid-susceptible CNS and 145 served 
as controls. Isolates were characterized by phenotypic and 
genotypic methods to species level, susceptibility to anti-
staphylococcal agents and clones.  Results: Among the 33 
linezolid-nonsusceptible CNS patients, 29 revealed  Staphy-
lococcus epidermidis and 4  Staphylococcus capitis . All  S. epi-
dermidis strains belonged to the ST22 clone (by multilocus 
sequence typing), 26 carried both C2534T and T2504A and 3 
strains were C2543T mutations.  S. capitis strains were strati-
fied as a common pulsed-field gel electrophoresis type and 
carried the G2576T mutation. Risk factors for linezolid-non-
susceptible CNS isolation were linezolid administration and 
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sitioning of t-RNA to the A-site  [2] . The development of 
resistance to linezolid is associated with the presence of 
mutations in 23S rRNA nucleotides, of which the most 
frequently reported are G2061, C2452, A2503, U2504, 
G2505, A2062, G2447, A2453, C2499, U2500 and G2576U 
 [2] . Other mechanisms of linezolid resistance include 
mutations in genes encoding L3 and L4 ribosomal pro-
teins and the presence of the transferable  cfr gene which 
encodes an rRNA methyltransferase  [2, 3] . Most reports 
underline the role of linezolid usage in hospitals for the 
emergence of resistance among Gram-positive bacteria 
 [1–4] . 
 Coagulase-negative staphylococci (CNS) are part of 
the normal skin flora. However, they cause severe infec-
tions in hospitalized patients (catheter-related blood-
stream infections, endocarditis, prosthetic joint infec-
tions, etc.). Often, they are multidrug resistant, leaving as 
the only therapeutic options newer antimicrobials such as 
linezolid  [1, 4, 5] . Reports from all over the world have 
identified low numbers of linezolid-resistant CNS and 
their presence is usually associated with hospitalized pa-
tients in intensive care units (ICU)  [1, 4–7] . Previous 
Greek studies have reported mutations conferring resis-
tance to linezolid among  Staphylococcus epidermidis from 
ICU wards of different hospitals. More specifically, the 
mutations T2504A and C2534T are closely associated 
with linezolid exposure and circulation of ST2 and ST22 
clones (sequence types)  [4, 8] . 
 In the present study, the risk factors for developing in-
fection or colonization with linezolid-nonsusceptible 
CNS during hospitalization in the adult medical/surgical 
ICU of a tertiary care university hospital were analyzed. 
The aim was to identify the resistance mechanisms of 
such strains and their genetic relationship in relation to 
antibiotic usage and other factors contributing to linezol-
id-nonsusceptible CNS spread in our setting.
 Methods 
 Patients  
 This single-center retrospective cohort study was conducted in 
the adult ICU of the University Hospital of Patras, Greece, a 700-
bed teaching hospital, from March 2010 to February 2012. The 
ethics committee of the University Hospital of Patras approved the 
study and waived the need for informed consent (approval No. 
571).
 Patients with an ICU stay of at least 6 days were classified into 
three groups. Group 1 (case patients) comprised 33 patients with 
positive CNS clinical specimens (intravenous catheter tips and/or 
blood) that exhibited reduced susceptibility to linezolid (mini-
mum inhibitory concentration, MIC  ≥ 2 mg/l), group 2 consisted 
of 68 ICU patients with intravenous catheter tip or blood cultures 
positive for linezolid-susceptible CNS (MIC  ≤ 1 mg/l) and patients 
with no CNS isolation served as group 3 (controls). Duplicate iso-
lates of the same patient were excluded from further analysis. 
Bloodstream infection, catheter-related or not, was associated with 
systemic symptoms or signs (fever, tachycardia, tachypnea, hypo-
tension, leukocytosis) with at least two positive blood cultures on 
separate occasions or a positive blood culture along with a positive 
culture by the same organism from an infected catheter  [9] . Posi-
tive blood or catheter tip cultures not meeting the above criteria 
were considered as contaminants.
 Phenotypic Identification and Antibiotic Susceptibility Testing 
 Of the 33 case patients, 15 had a linezolid-susceptible CNS iso-
late prior to final linezolid-nonsusceptible CNS recovery. All iso-
lates (48) were identified to species level by the Vitek 2 Advanced 
Expert System (bioMerieux SA, Marcy l’Étoile, France), while an-
tibiotic susceptibility testing was performed by the disk diffusion 
method against the following antistaphylococcal agents: cefoxitin, 
tetracycline, rifampicin, gentamicin, kanamycin, erythromycin, 
clindamycin, fusidic acid, ciprofloxacin and sulfamethoxazole-tri-
methoprim  [10] . MICs of oxacillin, vancomycin, linezolid and 
daptomycin were determined by Etest (bioMerieux)  [10] . 
 Molecular Analysis 
 All linezolid-nonsusceptible CNS were identified to species lev-
el by sequence analysis of the  tuf gene  [11] , whereas mutations in 
region V of 23S rDNA were investigated by PCR and sequence 
analysis  [8] . Sequence data were analyzed using Chromas (www.
technelysium.com.au/chromas.html). The presence of the  cfr gene 
was tested by PCR  [3] . The possible presence of mutations in ribo-
somal protein L4 was investigated by PCR followed by sequence 
analysis  [12] . 
 Clonal Identification 
 Clones were identified by means of  Sma I DNA macrorestric-
tion patterns and pulsed-field gel electrophoresis (PFGE)  [13] . Li-
nezolid-nonsusceptible and representative linezolid-susceptible  S. 
epidermidis from different pulsotypes and phenotypes were fur-
ther typed by multilocus sequence typing (http://www.mlst.net).
 Epidemiological ICU Data 
 Epidemiological data were collected from the ICU computer-
ized database (Criticus TM , University of Patras, Greece) and pa-
tients’ chart reviews. Parameters assessed included demographic 
characteristics (age, sex), severity scores of illness on admission, 
e.g. APACHE II (Acute Physiology and Chronic Health Evaluation 
II) score, SAPS II (Simplified Acute Physiology Score II) score, 
chronic illness prior to admission (e.g. diabetes mellitus, chronic 
obstructive pulmonary disease, chronic heart failure, chronic renal 
failure, malignancy), cortisone use, obesity, surgery, length of hos-
pitalization, presence of invasive catheters, endotracheal intuba-
tion, tracheotomy, type of antibiotic administration and enteral or 
parenteral nutrition. Enteric colonization by vancomycin-resis-
tant enterococci and nasal carriage of methicillin-resistant  Staphy-
lococcus aureus were also assessed by obtaining rectal and nasal 
samples from each patient upon admission and weekly afterwards, 
according to the surveillance program in the ICUs. The role of 
colonized or infected patients in nearby beds in dissemination of 
linezolid-nonsusceptible CNS strains was also investigated. Days 
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at risk were defined as days in the ICU until linezolid-nonsuscep-
tible CNS or linezolid-susceptible CNS isolation for the resistant 
and the susceptible study cases, respectively, and total ICU stay for 
the control group.
 Statistical Analysis 
 SPSS version 19.0 (SPSS, Chicago, Ill., USA) software was used 
for data analyses. Categorical variables were analyzed by using the 
Fisher exact test or the χ 2 test and continuous variables with the 
Mann-Whitney U test, as appropriate. Three different univariate 
analyses were performed: the first comprised linezolid-nonsuscep-
tible study cases versus controls, the second nonsusceptible study 
cases versus susceptible ones and, finally, susceptible study cases ver-
sus controls. Factors contributing to multicollinearity were excluded 
from the multivariate analysis. Backward stepwise multiple logistic 
regression analysis used all variables with a p < 0.1 from the uni-
variate analysis. Odds ratios and 95% confidence intervals were cal-
culated to evaluate the strength of any association. All statistical tests 
were 2-tailed and p < 0.05 was considered statistically significant.
 Results 
 Susceptibility Testing and Molecular Analysis 
 Among the 246 studied patients, 33 (13.4%) exhibited 
at least 1 positive linezolid-nonsusceptible CNS culture 
(linezolid MIC  ≥ 2 mg/l). From this group, 29  S. epidermi-
dis and 4  S. capitis strains were isolated; 5 patients had 
bloodstream catheter-related infection (identified by 
clinical signs and positive blood and intravenous catheter 
tip culture with the same strain), while the remaining 28 
cases were judged to be colonized ( table 1 )  [9] .
 Overall, 26  S. epidermidis strains showing linezolid 
MIC >256 mg/l carried both C2534T and T2504A muta-
tions ( Escherichia coli 23S rRNA gene numbering;  ta-
ble 1 ), while 3 carried only the C2534T mutation in the 
23S rDNA genes exhibiting linezolid MICs 2–4 mg/l. 
Linezolid-resistant  S. capitis strains (MICs: 6 and 32 
mg/l) carried the G2576T mutation. No strain carried 
the  cfr gene or any mutation in the L4 ribosomal protein 
gene. All linezolid-nonsusceptible  S. epidermidis strains 
belonged to the ST22 clone and to 3 PFGE types (A, C 
and E). Antibiotic resistance patterns of isolates were re-
lated to their PFGE types ( table 1 ). Linezolid-resistant  S. 
capitis strains belonged to a common PFGE type, ‘k’. 
From the group of 33 case patients, 15 had a linezolid-
susceptible  S. epidermidis that belonged to 2 (unrelated 
to A, C and E) PFGE types (B and D) and were classified 
as ST45 clone ( table 1 ). All CNS were methicillin resis-
tant. Mean MIC values among linezolid-nonsusceptible 
CNS were 1.7 mg/l for vancomycin (range 0.75–3 mg/l) 
and 0.4 mg/l for daptomycin (range 0.064–1 mg/l). The 
respective values for linezolid-susceptible CNS were 1.6 
mg/l (range 1.25–2 mg/l) and 0.3 mg/l (range 0.19–1 
mg/l).
 Risk Factors for Colonization or Infection by 
Linezolid-Nonsusceptible CNS 
 Risk factors associated with linezolid-nonsusceptible 
CNS colonization or infection from the univariate analy-
ses are shown in  table 2 , whereas results from multivariate 
 Table 1.  Phenotypic and genotypic characteristics of CNS isolated from the 33 study cases
Species Mutation MIC, mg/l PFGE ST Resistance pattern
(disk diffusion method)
Clinical samples Colonizing/
infecting, n
S. epidermidis C2534T, 
T2504A
256 (26) A (26) 22 FOX, GM, KAN, CC, FA, 
CIP, SXT
blood (19) 15/4
catheter tip (7) 6/1
C2534T 2 (1),
4 (1)
C (2) 22 FOX, GM, KAN, CC, CIP, SXTblood (2) 2/0
C2534T 3 (1) E (1) 22 FOX, KAN, CC, E blood (1) 1/0
– <1 (15) B (11) 45 FOX, GM, KAN, CC, FA, 
CIP, SXT, RA, E
blood (9) 9/0
catheter tip (2) 2/0
– D (4) 45 FOX, GM, KAN, CC, FA, 
CIP, SXT, E
blood (4) 4/0
S. capitis G2576T 6 (2),
32 (2)
k (4) n.a. FOX, GM, KAN, CC, FA, 
CIP, SXT, RA
blood (4) 4/0
 Values in parentheses indicate number of isolates. MIC: linezolid MIC identified by Etest. ST = Sequence types, identified by multi-
locus sequence typing; n.a. = not applicable; FOX = cefoxitin; RA = rifampicin; GM = gentamicin; KAN = kanamycin; E = erythromycin; 
CC = clindamycin; FA = fusidic acid; CIP = ciprofloxacin; SXT = sulfamethoxazole-trimethoprim.
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 Table 2.  Univariate analysis for risk factors for linezolid-nonsusceptible CNS isolation during ICU hospitalization
Characteristics Linezolid-
nonsusceptible 
CNS (n = 33)
Linezolid-
susceptible 
CNS (n = 68)
Controls
(n = 145)
pa pb pc
Days at risk 23.8±13.7 11.1±5.2 12.8±6.9 <0.001 <0.01 <0.05
Demographics
Age, years 47.5±18.0 54.1±18.6 56.8±19.9 <0.05 n.s. n.s.
Male gender 22 (66.7) 53 (77.9) 88 (60.7) n.s. n.s. n.s.
Comorbidities, number 1.0±1.0 0.9±1.1 0.8±1.1 n.s. n.s. n.s.
Diabetes mellitus 5 (15.2) 8 (11.8) 17 (11.7) n.s. n.s. n.s.
Chronic obstructive pulmonary disease 3 (9.1) 12 (17.6) 21 (14.5) n.s. n.s. n.s.
Chronic heart failure 2 (6.1) 6 (8.8) 12 (8.3) n.s. n.s. n.s.
Chronic renal failure 2 (6.1) 2 (2.9) 4 (2.8) n.s. n.s. n.s.
Malignancy 3 (9.1) 5 (7.4) 14 (9.7) n.s. n.s. n.s.
Obesity 12 (36.4) 21 (30.9) 27 (18.6) <0.05 n.s. n.s.
Cortisone use 4 (12.1) 4 (12.1) 12 (8.3) n.s. n.s. n.s.
Admission data
APACHE II score upon admission 17.9±9.7 15.9±6.5 15.6±6.6 n.s. n.s. n.s.
SAPS II score upon admission 39.0±15.6 37.1±10.3 37.3±12.7 n.s. n.s. n.s.
Previous hospitalization 15 (45.5) 36 (52.9) 67 (46.2) n.s. n.s. n.s.
Prior emergency surgery 15 (45.5) 27 (39.7) 51 (35.2) n.s. n.s. n.s.
Prior abdominal surgery 12 (36.4) 17 (25.0) 32 (22.1) n.s. n.s. n.s.
Number of antibiotics administered in ICU 5.4±1.8 3.3±1.1 3.2±1.4 <0.001 n.s. n.s.
Carbapenems 32 (97.0) 62 (91.2) 123 (84.8) 0.082 n.s. n.s.
Quinolones 7 (21.2) 10 (14.7) 22 (15.2) n.s. n.s. n.s.
3rd- or 4th-generation cephalosporins 3 (9.1) 4 (5.9) 19 (13.1) n.s. n.s. n.s.
β-Lactam/lactamase inhibitors 10 (30.3) 24 (35.3) 52 (35.9) n.s. n.s. n.s.
Colistin 27 (81.8) 21 (30.9) 34 (23.4) <0.001 <0.001 n.s.
Aminoglycosides 23 (69.7) 22 (32.4) 32 (22.1) <0.001 0.001 n.s.
Glycopeptides 24 (72.7) 64 (94.1) 117 (80.7) n.s. <0.01 <0.05
Metronidazole 9 (27.3) 7 (10.3) 20 (13.8) 0.070 <0.05 n.s.
Tigecycline 7 (21.2) 2 (2.9) 7 (4.8) <0.01 <0.01 n.s.
Linezolid 25 (75.8) 5 (7.4) 30 (20.7) <0.001 <0.001 <0.05
ICU procedures
Tracheotomy 29 (87.9) 41 (60.3) 87 (60.4) <0.01 <0.01 n.s.
Presence of catheters 26 (78.8) 38 (55.9) 77 (53.1) 0.010 <0.05 n.s.
Hemodialysis during ICU stay 11 (33.3) 7 (10.3) 16 (11.1) <0.01 <0.05 n.s.
Cortisone administration 25 (75.8) 40 (58.8) 82 (56.6) <0.05 n.s. n.s.
Parenteral nutrition 23 (69.7) 32 (47.1) 59 (40.7) <0.01 <0.05 n.s.
Enteral nutrition 27 (81.8) 53 (77.9) 109 (75.2) n.s. n.s. n.s.
Colonization/infection data
VRE rectal colonization 9 (27.3) 20 (29.4) 31 (21.4) n.s. n.s. n.s.
VRE infection 1 (3) 2 (2.9) 1 (0.7) n.s. n.s. n.s.
MRSA nasal colonization 0 (0.0) 6 (8.8) 8 (5.5) n.s. n.s. n.s.
MRSA infection 0 (0.0) 0 (0.0) 1 (0.7) n.s. n.s. n.s.
Mean number of linezolid-nonsusceptible 
CNS-positive patients in nearby beds per day 0.4±0.3 0.1±0.2 0.1±0.2 <0.001 <0.05 n.s.
 Data are presented as number of patients (with percentages in parentheses) or means ± SD. Colistin: only IV administration of co-
listin is included. Presence of catheters: all patients after ICU admission were intubated, mechanically ventilated and continuously 
monitored with a central venous catheter, an arterial catheter and a urinary catheter. Presence of catheters does not include the afore-
mentioned catheters. VRE = Vancomycin-resistant enterococcus; MRSA = methicillin-resistant S. aureus; n.s. = nonsignificant.
a Comparison between linezolid-nonsusceptible CNS patients vs. controls. b Comparison between linezolid-nonsusceptible CNS pa-
tients vs. linezolid-susceptible CNS patients. c Comparison between linezolid-susceptible CNS patients vs. controls.
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analyses appear in  table 3 . Compared to controls, hemo-
dialysis during ICU stay, aminoglycoside and/or linezolid 
administration and number of linezolid-nonsusceptible 
CNS-positive patients in nearby beds per day were sig-
nificantly associated with linezolid-nonsusceptible CNS 
isolation. Multivariate analysis of linezolid-nonsuscepti-
ble CNS-positive and linezolid-susceptible CNS-positive 
patients revealed that days at risk, linezolid administra-
tion and number of linezolid-nonsusceptible CNS-posi-
tive patients in nearby beds per day were significantly 
higher in the first group. Obesity, male gender and glyco-
peptide administration were independently associated 
with isolation of linezolid-susceptible CNS compared to 
controls. No statistically significant differences were de-
tected in the univariate analysis between infected and col-
onized patients by linezolid-nonsusceptible CNS.
 Figure 1 shows the number of new linezolid-nonsus-
ceptible CNS cases per month. During the last 12 months 
 Table 3.  Multivariate analysis of risk factors for linezolid-nonsusceptible CNS isolation during ICU stay
Characteristics p OR (95% CI)
Linezolid-nonsusceptible CNS vs. controls
Hemodialysis during ICU stay 0.048 3.7 (1.0–13.3)
Aminoglycoside administration 0.006 4.9 (1.6–15.3)
Linezolid administration 0.001 6.8 (2.2–21.5)
Mean number of linezolid-nonsusceptible CNS-positive 
patients in nearby beds per day <0.001 23.4 (4.1–134.8)
Linezolid-nonsusceptible CNS vs. linezolid-susceptible CNS
Days at risk 0.003 1.2 (1.1–1.3)
Linezolid administration <0.001 27.2 (5.3–138.8)
Mean number of linezolid-nonsusceptible CNS-positive 
patients in nearby beds per day 0.011 32.6 (2.3–472.5)
Linezolid-susceptible CNS vs. controls
Obesity 0.012 2.6 (1.2–5.3)
Male gender 0.003 2.9 (1.4–5.9)
Glycopeptide administration 0.003 5.7 (1.8–18.2)
 OR = Odds Ratio; CI = confidence interval.
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 Fig. 1. Isolation of linezolid-nonsusceptible CNS per month.  
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of the study (March 2011 to February 2012), 21 out of 112 
patients (18.8%) were linezolid-nonsusceptible CNS-
positive compared to 12 out of 124 (9.7%) during the first 
12 months (p = 0.038). 
 Discussion 
 The widespread use of linezolid due to the reduced 
activity of glycopeptides against Gram-positive cocci has 
led to the emergence and dissemination of linezolid re-
sistance. Recently, Gu et al.  [1] reported a total of 351 
linezolid-resistant CNS cases from Europe, North 
 America, South America and Asia (53.6, 42.5, 2.8 and 
1.1%, respectively). All isolates were resistant to methicil-
lin, as well as to a wide range of antistaphylococcal agents, 
underlying the need for accurate detection of resistance 
to linezolid and judicious use of the drug, since pro-
longed treatment induces resistance  [1] . The isolates of 
the present study were also methicillin resistant, with an-
tibiotic resistance patterns correlating to their PFGE 
types. Previous studies in Greece, including strains from 
our institution, identified linezolid-resistant CNS carry-
ing C2534T, G2576T and T2504A mutations, the latter 
of which is associated with high levels of linezolid MIC 
 [4, 8] . This fact is also verified in the present study, where 
26 cases of  S. epidermidis expressing high levels of line-
zolid MIC carried both C2534T and T2504A mutations. 
Furthermore, the  S. epidermidis  ST22 clone seems to cir-
culate steadily in our setting  [4] . Although 3  S. epidermi-
dis strains were linezolid susceptible (MIC: 2–4 mg/l), 
they were positive for the presence of the C2534T muta-
tion. In a study by Ferreira et al.  [14] among 101 staphy-
lococci phenotypically tested, the range of linezolid MIC 
was 0.5–4 mg/l, but no molecular analysis was performed. 
In another study, linezolid nonsusceptibility among 
staphylococci was associated with the G2576T mutation 
in 23S rDNA, whereas 5 isolates carried the mobile  cfr 
element  [15] . Additionally, the presence of the G2576T 
mutation in 23S rDNA (mutations in L3 or L4 genes) re-
sulted in reduced susceptibility to linezolid among en-
terococci  [16, 17] . 
 Importantly, we report for the first time that linezolid-
resistant  S. capitis strains bear the G2576T mutation and 
belong to a common PFGE type. Resistance to linezolid 
among  S. capitis was also identified in China due to the 
presence of a novel C2104T mutation  [18] .
 Linezolid administration is reported to be one of the 
most important risk factors for linezolid-resistant Gram-
positive cocci isolation in hospital outbreaks  [4–7, 19] . 
However, it should be noted that there are not enough 
data regarding the risk factors contributing to the emer-
gence of linezolid-resistant CNS  [4–7] . 
 In our studied group, 8 out of 33 patients did not re-
ceive linezolid for at least 6 months prior to admission 
and during their ICU stay, suggesting that linezolid ad-
ministration, although important, is not by itself the only 
factor contributing to the spread of linezolid-resistant 
pathogens. Additionally, ICUs remain the source of silent 
dissemination; therefore, the determination of risk fac-
tors involved in potential linezolid-resistant CNS out-
breaks in such settings provides essential information for 
understanding the emergence and evolution of future 
outbreaks  [4–6] .
 Furthermore, even though it has been previously 
suggested  [4, 6, 19] , this is the first study proving, with 
multivariate analysis, that the presence of linezolid-
nonsusceptible CNS-positive patients in nearby beds 
plays an important role in the dissemination of these 
pathogens. 
 Increased length of stay was also found to be an impor-
tant risk factor for the evolution and isolation of linezol-
id-nonsusceptible CNS. As mentioned in other studies 
regarding multidrug-resistant pathogens, being hospital-
ized near an already colonized patient usually increases 
the chances of acquiring the microorganism. Prolonged 
ICU stay predisposes to infection, especially when pa-
tients receive linezolid as an anti-Gram-positive coverage 
 [20, 21] .
 An interesting finding was that colistin and aminogly-
cosides administration was identified by univariate anal-
ysis as a risk factor for the isolation of linezolid-nonsus-
ceptible CNS compared to patients with linezolid-suscep-
tible isolates and controls ( table  2 ). This result can be 
explained by the fact that colistin and aminoglycosides 
are administered in combination with linezolid to pa-
tients not responding to carbapenems and glycopeptides. 
Therefore, no correlation exists between colistin or ami-
noglycoside administration and the spread of CNS resis-
tant to linezolid.
 It is noteworthy that all linezolid-nonsusceptible CNS 
belonged to common clones (ST22 for  S. epidermidis and 
pulsotype k for  S. capitis ). Also, susceptible strains from 
the same patients belonged to different PFGE and se-
quence types (ST45), suggesting a clonal-related dissemi-
nation of linezolid-resistant strains  [4, 6] . However, since 
different mutations were simultaneously detected among 
these strains, a continuous evolution of multidrug-resis-
tant bacteria also occurs under the pressure of antibiotic 
usage among critically ill ICU patients. The number of 
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infected patients by linezolid-nonsusceptible CNS was 
low in the present study, as also reported by Potoski et al. 
 [19] . 
 Conclusions 
 Besides linezolid usage, patient-to-patient transmis-
sion of linezolid-nonsusceptible CNS occurs among ICU 
patients, suggesting the necessity for strict infection con-
trol measures such as adequate central venous catheter 
handling and hand hygiene of health care workers.
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